Reimagining Medicine Q2 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Novartis pipeline in Phase 3
Conclusions
Appendix
Innovation: Clinical trials
References
Abbreviations
INNOVATION
6 lead indications
Lead indication
Solid Tumors
Hematology
Code
Name
Mechanism
Indication(s)
Code
Name
AAA617
PluvictoⓇ
Radioligand therapy target PSMA Metastatic castration-resistant prostate cancer (mCRPC), pre-taxane
Metastatic hormone sensitive prostate cancer (mHSPC)
ABL001
ETB115
Scemblix®
PromactaⓇ
Mechanism
BCR-ABL inhibitor
AAA6011
LutatheraⓇ
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
tumors (GEP-NET 1L G3)
BYL719
JDQ443
Piqray®
JDQ443
PI3Ka inhibitor
Ovarian cancer
LNP023
MBG453
VAY736
iptacopan
sabatolimab
janalumab
KRAS inhibitor
2/3L Non-small cell lung cancer
LEE011
Kisqali®
CDK4/6 Inhibitor
VDT482
tislelizumab
PD1 inhibitor
HR+/HER2- BC (adj)
1L ESCC
1L Small cell lung cancer
Localized ESCC
Thrombopoietin receptor
(TPO-R) agonist
CFB inhibitor
TIM3 antagonist
BAFF-R inhibitor
Indication(s)
Chronic myeloid leukemia, 1st line
Radiation sickness syndrome
Atypical hemolytic uraemic syndrome
Myelodysplastic syndrome
1L Immune Thrombocytopenia
2L Immune Thrombocytopenia
warm Autoimmune Hemolytic Anemia
Adj/Neo adj. NSCLC
1L Gastric cancer
1L Urothelial cell cancer
Cardiovascular
Immunology
Code
Name
Code Name
KJX839 Leqvio®
AIN457
CosentyxⓇ
Mechanism
IL17A inhibitor
Indication(s)
Giant cell arteritis
Mechanism
siRNA (regulation of LDL-C)
Indication(s)
CVRR-LDLC
Primary prevention
Hyperlipidemia, pediatrics
IGE025
LOU064
Xolair
IgE inhibitor
remibrutinib
BTK inhibitor
QGE031 ligelizumab
IgE inhibitor
VAY736 ianalumab
Neuroscience
Name
Code
AMG334 AimovigⓇ
BAF312 Mayzent®
LOU064 remibrutinib
OAV101 AVXS-101
OMB157 Kesimpta®
1. 177 Lu-dotatate in US.
Polymyalgia rheumatica
Rotator cuff tendinopathy
Food allergy
Chronic spontaneous urticaria
BAFF-R inhibitor
Chronic spontaneous urticaria, pediatrics
Food allergy
Sjögren's
Lupus Nephritis
Systemic lupus erythematosus
LNP023 iptacopan
CFB inhibitor
IgA nephropathy
C3 glomerulopathy
TQJ230 pelacarsen
ASO targeting Lp(a)
Others
Name
Mechanism
C3 glomerulopathy, pediatrics
IC-MPGN
Secondary prevention of cardiovascular events in patients with
elevated levels of lipoprotein (a) (CVRR-Lp(a))
Indication(s)
PGH-1 (artemisinin combination Malaria, uncomplicated (<5kg patients)
therapy)
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
BTK inhibitor
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMN1 gene replacement therapy SMA IT administration
Code
IB&GH
COA566 CoartemⓇ
Ophthalmology
RTH258 BeovuⓇ
VEGF Inhibitor
CD20 Antagonist
34 Investor Relations | Q2 2023 Results
Multiple sclerosis, pediatrics
Biosimilars
Code
GP2411
SOK583
Name
denosumab
aflibercept
Diabetic retinopathy
Mechanism
anti RANKL mAb
VEGF inhibitor
Indication(s)
Osteoporosis (same as originator)
Ophthalmology indication (as originator)
U NOVARTIS | Reimagining MedicineView entire presentation